Neptune is Nominated as a Finalist for the Nutraceutical & Business Technology Awards 2011 and Prolongs US IR Agreement

Laval, Québec, CANADA – April 14, 2011 – Neptune Technologies & Bioressources Inc. (“Neptune”) (NASDAQ.NEPT - TSX.V.NTB) is proud to announce that it is a finalist for the Nutraceutical & Business Technology (NBT) Awards 2011, in the category of Outstanding Application in Health Management.

After much deliberation and due-diligences the judges submitted a shortlist of finalist. Neptune is one out of the five companies announced as a finalist for the NBT Awards, in the much esteemed category of Outstanding Application in Health Management. The high standard of the NBT Awards has contributed to making this event a great success. The winners will be announced on the night of the Awards at the Gala dinner to be held Wednesday May 11th, during the nutraceutical event of Vitafoods Europe in Geneva. ‘‘We are very proud to be finalist for an NBT award, especially in the Outstanding Application in Health Management category. Being in the top finalist for this category, along with industry pioneers, shows a worldwide recognition of the benefits of NKO®’’ stated Sabrina Di Blasio, Director, Marketing.

On another subject, Neptune prolongs its IR agreement with CEOcast to continue the development an exhaustive IR strategy in the US. As per the extension of the IR agreement, CEOcast has been granted options to purchase 25,000 common shares of Neptune at a price of $2.50 per share.  The options will vest in equal amounts at the rate of 15% per quarter with a three-year term expiring on March 15th, 2014.

About Neptune Technologies & Bioressources Inc.

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune’s products are marketed and distributed in over 20 countries worldwide.

About Acasti Pharma Inc.

Acasti Pharma is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma’s proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by potent antioxidants. Acasti Pharma is focusing initially on treatments for chronic cardiovascular conditions within the over-the-counter, medical food and prescription drug markets.

About NeuroBioPharm

NeuroBioPharm is pursuing pharmaceutical neurological applications, and a clinical study for a medical food product with a multinational partner is already initiated. The development of a prescription drug candidate is currently in progress. Advanced clinical development and commercialization is planned to be carried out with multinational partners.

"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."